Der Stabilisator (auch fürs Depot?)
Seite 1 von 4 Neuester Beitrag: 25.04.21 01:42 | ||||
| Eröffnet am: | 06.01.15 08:40 | von: erfg | Anzahl Beiträge: | 99 |
| Neuester Beitrag: | 25.04.21 01:42 | von: Lenadsxxa | Leser gesamt: | 50.662 |
| Forum: | Hot-Stocks | Leser heute: | 9 | |
| Bewertet mit: |  | |||
| Seite: < | 2 | 3 | 4 > | ||||
Wie lange wursteln die denn bereits herum? Bei 105 Mio. Verlustvorträgen,einem negativen Eigenkapital und recht hohen jährlichen Verlusten, ist von einer nachhaltigen Wachstumsstrategie nicht viel zu erkennen. Und die Präsentationen erinnern einen eher an dubiose Werte.
http://finance.yahoo.com/q/bs?s=CTSO+Balance+Sheet&annual
Es läuft gerade eine KE.
Wir werden ja sehen, ob die Anleger bereit sind zu investieren!
Die Absatzzahlen haben sich in den letzten Quartalen vervielfacht.
Also abwarten und Teetrinken!
Brean Capital analyst Jonathan Aschoff was out pounding the table on Cytosorbents Corp (NASDAQ:CTSO) Thursday, reiterating a Buy rating and price target of $25, which implies an upside of 172% from current levels:
New Case report in Int. Journal of art. Organs: CytoSorb again was life saving.....
From PubMede, Int. Journal of art. Organs, 2015 Feb 3;0(0):0. doi: 10.5301/ijao.5000382. [Epub ahead of print]
First successful combination of ECMO with cytokine removal therapy in cardiogenic septic shock: a case report.
PURPOSE: A new hemoadsorption device intended as adjunctive treatment for patients with elevated cytokine levels in the setting of SIRS and sepsis has shown promising results. We report on the beneficial application of the device in a patient with cardiogenic septic shock receiving combined extracorporeal life support with rECMO, LVAD, and CVVH despite his highly septic condition.
METHODS: A 39-year-old patient presented with fulminant ARDS and cardiogenic septic shock. A veno-arterial ECMO was implanted for circulatory support. During the course of illness, the patient developed acute renal failure in addition to his chronic renal insufficiency, making initiation of CVVH necessary. Due to a complete cardiac arrest in both ventricles, a left ventricular assist device (LVAD) in combination with right ECMO (rECMO) was implanted despite manifest septic conditions. In the post-operative course IL-6 levels and vasopressor dosages increased drastically. A CytoSorb hemoadsorption device was therefore installed in the CVVH circuit and 3 sessions were run during the following 4 days.
RESULTS: During CytoSorb treatment, inflammatory markers IL-6, procalcitonin, and C-reactive protein decreased concomitant with significantly reduced vasopressor support. No adverse device-related side effects were documented during or after the treatment sessions.
CONCLUSIONS: This is the first clinical case report of a highly septic patient treated with the combined use of LVAD, rECMO, CVVH, and CytoSorb. The combination was practical, technically feasible, and beneficial for the patient. This combination represents a reasonable approach to improve survival in patients with multiple organ dysfunction necessitating several organ supportive techniques.
Quelle: Nasdaq-Message-Board
Research analysts at Brean Capital set a $25.00 target price on shares of Cytosorbents Corporation (NASDAQ:CTSO) stock in a report released on Thursday. The firm currently has a a “buy” rating on the stock. Cytosorbents Corporation (NASDAQ:CTSO) in last trading activity moved up 10.01% to close at $10.00. Company weekly performance is 24.07%. Cytosorbents Corporation (NASDAQ:CTSO) is -22.30% away from its 52 week high.
Das ist immer der aktuelle Kurs!
MLV analyst Raghuram Selvaraju came out today with an extremely bullish call on Cytosorbents Corp (NASDAQ:CTSO), initiating a Buy rating and a $30 price target, which represents a potential upside of 170% from where the stock is currently trading. Cytosorbents shares are trading down $0.08 or 0.74% to $10.79.
Selvaraju wrote, “In our view, CytoSorbents is an unusual technology platform firm with a marketed product in Europe that is applicable across several indications in the hospitalbased sector. This product, CytoSorb®, has already generated positive proof-ofconcept data and could achieve regulatory approval in the U.S. next ...